Icon Group operates Australia’s largest private cancer clinical trials program. Across the network, patients and clinicians participate in national and international trials in haematology, medical oncology and radiation oncology. This includes trials sponsored by the pharmaceutical industry, along with collaborative studies undertaken in partnership with various universities and collaborative groups.
Icon Group operates Australia’s largest private cancer clinical trials program.
Icon has been an active contributor in a number of milestone trials that have seen significant advancements in cancer drugs including the ground-breaking trial that changed the use of Herceptin in HER2-positive breast cancer cases. This also extends to radiation oncology trials including TRANSFORM – a study focusing on stereotactic radiation therapy as an alternative to systemic treatment in men with oligometastatic prostate cancer; and SHRINC – a trial assessing the use of stereotactic hypofractionated radiation therapy for multiple (3-10) cerebral metastases. Icon currently has 300 patients on active trials – 59 clinical trials open for recruitment and 51 active studies with patients currently in treatment and follow-up. Over 75% of these trials are focused in the growing area of immunotherapy, with a large cohort in Phase 1 – or first in human – trials. Icon is committed to further extending our research partnerships and activities to continue to provide more patients and clinicians with access to new and emerging advances in cancer treatment.
In 2019, Icon Group signed a Memorandum of Understanding (MOU) with Queensland’s leading medical research institute, QIMR Berghofer. The MOU will better enable Icon and QIMR to translate cutting-edge research into clinical practice, with key areas of interest including new ways of diagnosing cancer and sharing information that could be used to genetically sequence cancers.
Icon Group is committed to further extending our research partnerships and activities to continue to provide patients and clinicians with access to new and emerging advances in cancer treatment. For more information on current clinical trials and/or becoming a research partner, refer to the Research page on the Icon Cancer Centre Australia website.
Icon’s research function is in part supported by Icon Cancer Foundation, a not-for-profit entity enabling access and a greater understanding of clinical trials.